Enanta Pharmaceuticals Inc (ENTA)

[willyw]

ABT-493 + ABT-530- Geno- 3 EASL Late Breaker

I cannot view the text of the complete abstract, but look at this presentation;

(type ABT-493 + ABT-530 into the search engine- red box
it will provide presentations; click on late breakers. ~W)

https://events.easl.eu/EventProgramme/ILC2016.aspx


16:00 - 16:15
Abstract LBO1: 100% SVR4 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS
Presenter:
Paul Y. Kwo (United States)

=============
This is a late breaker.
keep in mind that it is merely SVR-4,
so there is a possibility of a viral relapse, and it would be more likely in cirrhotics.
Nor do we know the sample size.

This seems very bullish to me. To be clear, there will be other great presentations by competitors, but this looks very positive.

Genotype 3 looked a little iffy (from non-optimized dosing) to me from earlier posted data. Were I to guess it looks like 100% across all genotypes 12 weeks, and it looks as though it could be 8 weeks without riba as well.

More to come